Artiva Biotherapeutics

Artiva Biotherapeutics is a clinical-stage biotechnology company dedicated to developing natural killer (NK) cell-based therapies aimed at treating severe autoimmune diseases. Our innovative lead product, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy designed for use alongside B-cell targeted monoclonal antibodies, offering efficient and accessible treatment options in community settings.